Download PDF
Thromb Haemost 1971; 25(03): 532-544
DOI: 10.1055/s-0038-1654327
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Quantitative Determination of Platelet Factor 3 Activity

J Polasek
1   Blood Coagulation and Fibrinolysis Laboratory (Head: PD Dr. F. Duckert) of the University Department of Medicine (Head: Prof. F. Koller), Bürgerspital, Basle, Switzerland
,
F Duckert
1   Blood Coagulation and Fibrinolysis Laboratory (Head: PD Dr. F. Duckert) of the University Department of Medicine (Head: Prof. F. Koller), Bürgerspital, Basle, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Also available at
    Permissions and Reprints

Summary

A method for the quantitative determination of platelet factor 3 (PF 3) is described. It is based on the prothrombin consumption and allows the determination of the total PF 3, of the PF 3 made available under various conditions and of PF 3 like activity.

The material to be tested is recalcified in the presence of a normal PPP pool to maintain the intrinsic clotting factors in the optimal concentration range. After an appropriate incubation the coagulation is stopped by a citrate solution and the clot removed. The residual prothrombin activity in citrated serum is indirectly proportional to the PF 3 activity. This activity can be expressed in per cents by means of a reference curve which can be established with Cephaloplastin (Dade) dilutions. The 100% value is given by the total average PF 3 activity when the platelet count in PRP is adjusted to 100,000 platelets/mm3. An appropriate correction is needed when the prothrombin concentration is too low in the tested PRP.

In 50 healthy blood donors the PF 3 activity ranged between 70-130% with quite small day to day variations.

 

  • References

  • 1 Allain J. P, Gaen J. L’analyse des fonctions plaqnettaires: Mesure de l’activité coagulante des plaquettes. Rev. franç. Études clin, et Biol 12: 732-736 1967;
    PubMedGoogle Scholar
  • 2 Allcjaersig N, Abe T, Seegers W. H. Purification and quantitative determination of platelet factor 3. Amer. J. Physiol 181: 304-308 1955;
    PubMedGoogle Scholar
  • 3 Boczarow B. L’intérêt du test de consommation de la prothrombine pour la mise en évidence des déficits plaquettaires qualitatifs. Hémostase 01: 285-289 1961;
    PubMedGoogle Scholar
  • 4 Bowie E. J. W, Thompson J. H. R, Owen Jr G. A. Standardization of platelets in thromboplastin generation test. Amer. J. clin. Path 44: 673-677 1965;
    PubMedGoogle Scholar
  • 5 BucJcwalter J. A, Blythe W. B, Brinkhous K. M. Effect of blood platelets on prothrombin utilisation of dog and human plasmas. Amer. J. Physiol 159: 316-321 1949;
    PubMedGoogle Scholar
  • 6 Egli H. Eine quantitative Einstufenmethode zur Bestimmung des Thrombozytenfaktors 3. Thrombos. Diathes. haemorrh. (Stuttg) 06: 533-546 1961;
    PubMedGoogle Scholar
  • 7 Erdogan G. Thromboplastic activity of white cells. Blut 17: 276-278 1968;
    CrossrefPubMedGoogle Scholar
  • 8 Fantl P, Ward H. A. The thromboplastin component of intact platelets is present in masked form. Aust. J. exp. Biol. med. Sci 36: 499 1958;
    PubMedGoogle Scholar
  • 9 Farska I, Pudlak P. Determination of platelet factor 3 by a modified prothrombin consumption test. Scand. J. Haemat 04: 187-192 1967;
    PubMedGoogle Scholar
  • 10 Ferguson J. H, Lewis J. H, Fresh J. W. The two-stage “prothrombin” assay in study of bleeding and clotting disorders. Yale J. Biol. Med 28: 253-264 (1955/56).
    PubMedGoogle Scholar
  • 11 Hardisty R. M, Hutton R. A. The kaolin clotting time of platelet-rich plasma: a test of platelet factor-3 availability. Brit. J. Haemat 11: 258-268 1965;
    CrossrefPubMedGoogle Scholar
  • 12 Husom O. A one stage method for the assay of platelet factor 3. Scand. J. clin. Lab. Invest 13: 609-618 1961;
    CrossrefPubMedGoogle Scholar
  • 13 Inceman S, Tangün Y. Platelet factor 3 availability in Glanzmann’s disease. Isr. J. med. Sci 05: 1259-1262 1969;
    PubMedGoogle Scholar
  • 14 Koller F, Loeliger E. A, Duckert F. Experiments on a new Clotting Factor (Factor VII). Acta haemat. (Basel) 06: 1-18 1951;
    CrossrefPubMedGoogle Scholar
  • 15 Kubisz P, Pinkas J, Caen J. Acid phosphatase availability. Isr. J. med. Sci 06: 494-497 1970;
    PubMedGoogle Scholar
  • 16 Marcus A. J. The role of lipids in blood coagulation. Advanc. Lip. Res 04: 1-37 1966;
    PubMedGoogle Scholar
  • 17 Merskey C. The consumption of prothrombin during coagulation: The defect in haemophilia and thrombocytopenic purpura. J. clin. Path 03: 130-141 1950;
    CrossrefPubMedGoogle Scholar
  • 18 Owen Jr. ACh, Thompson Jr. J. H. Soyabean phosphatides in prothrombin-consumption and thromboplastin-generation tests : Their use in recognizing “thrombasthénie hemophilia”. Amer. J. clin. Path 33: 197-208 1960;
    PubMedGoogle Scholar
  • 19 Polasek J, Kubisz P. Acid phosphatase and Platelet Factor 3. Scand. J. Haemat 05: 390-400 1968;
    PubMedGoogle Scholar
  • 20 Quick A. J. Prothrombin consumption test. Amer. J. clin. Path 45: 105-109 1966;
    PubMedGoogle Scholar
  • 21 Rabiner S. F, Hrodek O. Platelet factor 3 in normal subjects and patients with renal failure. J. clin. Invest 47: 901-912 1968;
    CrossrefPubMedGoogle Scholar
  • 22 Shinowara G. Y. The nature of the lipoprotein of human platelets and erythrocytes. In: Johnson S. A, et a. l. Blood platelets. 347-356 Brown and Co; Boston: 1961
    Google Scholar
  • 23 Spaet T. h, Cintron J. Studies on platelet factor 3 availability. Brit. J. Haemat 11: 269-275 1965;
    CrossrefPubMedGoogle Scholar
  • 24 Stefanini M, Campbell E. W. Studies on platelets. XII. Isolation and purification of platelet thromboplastic factor: its physicochemical and biologic properties “in vitro” and “in vivo”. Rev. Haemat 09: 576-585 1954;
    PubMedGoogle Scholar
  • 25 Weiss A. J, Eichelberger Jr. J. W. The detection of platelet defects in patients with mild bleeding disorders. Use of a quantitative assay for platelet factor 3. Amer. J. Med 32: 872-883 1962;
    PubMedGoogle Scholar